Oscar Williams-Grut, City Editor @OscarWGrut7 July 2014
Life sciences company Abzena today raised £20 million on AIM, in a public offering that values the company at £77.9 million.
The 80p-a-share offer marks the fourth float this year of a company backed by Imperial Innovations, the investment company tied to Imperial College that focuses on commercialisation of academic research.
Imperial Innovations’ highest-profile offering this year has been Circassia, the biomedical company aiming to develop allergy cures. Circassia raised £200 million in March on a £581 million valuation.
As part of Abzena’s float Imperial Innovations bought a further five million shares in the business, giving it a stake of 23.6%.
American CV checker ClearStar today also revealed plans to list on AIM this week.
